Result of AGM

RNS Number : 1932V

N4 Pharma PLC

03 April 2023

 

3 April 2023

N4 Pharma plc

("N4 Pharma" or the "Company")

Result of Annual General Meeting

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, is pleased to announce that at its annual general meeting ("AGM"), held earlier today, all resolutions were duly passed.

Resolution	For	For%	Against	Against %	Total	Witheld votes*
Ordinary Resolution 1 - To receive the annual report and audited accounts for the year ended 31 December 2022	20,267,523	99.37%	127,579	0.63%	20,395,102	19,729
Ordinary Resolution 2 - To re-elect John Chiplin as a Director of the Company	20,004,322	98.08%	390,780	1.92%	20,395,102	19,729
Ordinary Resolution 3 - To re-elect Luke Cairns as a Director of the Company	20,165,927	98.88%	229,175	1.12%	20,395,102	19,729
Ordinary Resolution 4 - To re-elect Chris Britten as a Director of the Company	20,004,322	98.87%	229,175	1.13%	20,233,497	181,334
Ordinary Resolution 5 - To re-appoint Saffery Champness LLP as the Companyʼs auditor and to authorise the Directors to determine their remuneration	20,037,518	98.25%	356,384	1.75%	20,393,902	20,929
Ordinary Resolution 6 - To authorise the Directors to allot shares	19,996,465	98.36%	333,237	1.64%	20,329,702	85,129
Special Resolution 7 - To disapply pre-emption rights	20,003,065	98.39%	326,437	1.61%	20,329,502	85,329

*Please note a vote withheld is not a vote in law and is not counted in the calculation of votes validly cast for or against a resolution.

Enquiries:

N4 Pharma plc
Nigel Theobald, CEO	Via IFC Advisory
Luke Cairns, Executive Director
SP Angel Corporate Finance LLP	Tel: [phone]
Nominated Adviser and Joint Broker
Matthew Johnson/Kasia Brzozowska (Corporate Finance)
Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking)
Turner Pope Investments (TPI) Limited	Tel: [phone]
Joint Broker
Andy Thacker James Pope
IFC Advisory Ltd	Tel: [phone]
Financial PR
Graham Herring
Zach Cohen

About N4 Pharma

N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for cancer and vaccine treatments using its unique silica nanoparticle delivery system called Nuvec®.

N4 Pharma's business model is to partner with companies developing novel antigens for cancer and vaccine treatments to use Nuvec® as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity.  As these products progress through preclinical and clinical programs, N4 Pharma will seek to receive up front payments, milestone payments and ultimately royalty payments once products reach the market.

 

END

 

 

RAGBXGDSIGGDGXX